ArticleIn vivo (Athens, Greece)

Prostate-specific Antigen Decline During Primary Androgen-deprivation Therapy for Predicting Response and Survival in Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide.

Yujiro Nagata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.